MedTrace Logo

Multi-level School-based Intervention to Improve HPV Vaccine Uptake and Completion in South Africa

NCT05919901 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2025-10-31

No results posted yet for this study

Summary

Human Papillomavirus (HPV) is the most common sexually transmitted infection globally, and is causally linked to cervical, anogenital, and oropharyngeal cancers. HPV-associated cancers have a disproportionate impact in low-resource settings and nowhere is this evident than in South Africa, which has a uniquely vulnerable population due to the convergence of the largest HIV epidemic globally, with HPV rates of up to 85% in young women under the age of 25. For the clinical trial phase of this study, we intend to evaluate preliminary effects of a communications strategy and key criteria to advance to a full scale hybrid type 2 trial. Our systems-focused approach leverages established partnerships with area schools serving diverse populations who are not always effectively served by traditional healthcare channels.

Conditions

Interventions

OTHER

HPV Vaccine Communication Strategy

The intervention will include health promotions materials and provision of HPV vaccine

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Brigham and Women's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-26
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05919901 on ClinicalTrials.gov